Monday, July 20 2026

40 drugs not available in market due to pending govt price approvals
Around 40 medicines that have already been registered in Pakistan remain unavailable to patients because the federal government has yet to approve their prices. The delay has left thousands of patients, including those battling cancer, diabetes and other life-threatening diseases, with limited treatment options, forcing many to depend on costly personal imports or smuggled and unregistered medicines. The pending medicines include Pembrolizumab (Keytruda), one of the world’s leading immunotherapy drugs approved internationally for more than 20 cancers, including lung, breast, cervical, kidney, bladder, stomach and skin cancers. Other important cancer medicines awaiting price notification include Nivolumab, Irinotecan, Dasatinib and Leucovorin.
Related news categories: business economic-indicators pharma psx stock-exchanges

Thursday, July 16 2026

Pharmaceutical, Healthcare B2B investment conference begins from 17th
Pakistan is all set to host a two-day Pharmaceutical and Healthcare business-to-business (B2B)investment conference in Islamabad from 17-18 July aimed at promoting investment and industrial cooperation in the pharmaceutical, healthcare, and biotechnology sectors. This was stated by Federal Minister for National Health Services and Regulations, Syed Mustafa Kamal, while addressing a joint press conference, along with Federal Minister for Board of Investment, Qaiser Ahmed Sheikh, and Special Assistant to the Prime Minister (SAPM) for Industries and Production, Haroon Akhtar Khan, here on Wednesday.
Related news categories: business economic-indicators misc pharma